Document:

Employment Agreement

 EXHIBIT 10.2 
 EMPLOYMENT AGREEMENT 
 This Employment Agreement (this “Agreement”) is entered into
effective August 1, 2008 (the “Effective Date”), by and between DaVita Inc. (“Employer”) and Allen Nissenson (“Employee”). 
 In consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the parties hereto, intending to be legally bound hereby, agree as follows: 
 Section 1. Employment and Duties. Employer hereby employs Employee to serve initially as Chief Medical Officer. Employee accepts such
employment on the terms and conditions set forth in this Agreement. Employee shall perform the duties of Chief Medical Officer as determined by Chief Executive Officer and/or the Board of Directors or any additional or different duties or jobs as
the Company deems appropriate. Employee shall work out of Employer’s corporate head quarters. Employee agrees to devote substantially all of his time, energy, and ability to the business of Employer on a full-time basis and shall not engage in
any other business activities during the term of this Agreement, provided however, Employee may pursue normal charitable activities so long as such activities do not require a substantial amount of time and do not interfere with his
ability to perform his duties. Employee agrees that he shall not serve on the board of directors of any not-for-profit or for-profit company, provide any consulting services to another company, or be paid for any speaking engagement without the
express written approval of the Chief Executive Officer or the Board of Directors. Employee shall at all times observe and abide by the Employer’s policies and procedures as in effect from time to time. 
 Section 2. Compensation. In consideration of the services to be performed by Employee hereunder, Employee shall receive the following
compensation and benefits: 
 2.1 Base Salary. Employer shall pay Employee a base salary of $650,000 per annum, less standard
withholdings and authorized deductions. Employee shall be paid consistent with Employer’s payroll schedule. The base salary will be reviewed from time to time. Employer, in its sole discretion, may increase the base salary as a result of any
such review. 
 2.2 Benefits. Employee and/or his family, as the case may be, shall be eligible for participation in and shall receive
all benefits under Employer’s health and welfare benefit plans (including, without limitation, medical, prescription, dental, disability, and life insurance) under the same terms and conditions applicable to most executives at similar levels of
compensation and responsibility. 
 2.3 Performance Bonus. 
 (a) Employee shall be eligible to receive a discretionary performance bonus (the “Bonus”) between zero and $350,000, payable in a manner
consistent with 

 
Employer’s practices and procedures. The amount of the Bonus, if any, will be decided by the Chief Executive Officer and/or the Board of Directors or
the Compensation Committee of the Board in his/her/its sole discretion. The Bonus that is paid in 2009 for work performed in 2008 shall be pro-rated based on Employee’s time in his position, and Employer shall pay Employee a minimum Bonus of
50% of his pro-rated Bonus potential. 
 (b) Employee must be employed by Employer (or an affiliate) on the date any Bonus is paid to be
eligible to receive such Bonus and, if Employee is not employed by Employer (or an affiliate) on the date any Bonus is paid for any reason whatsoever, Employee shall not be entitled to receive such Bonus. 
 2.4 Vacation. Employee shall have vacation, subject to the approval of the Chief Executive Officer. 
 2.5 Stock Appreciation Rights. Employer shall issue a grant to Employee of stock-settled
Stock Appreciation Rights (“SSARS”) on a base number of 35,000 shares of DaVita common stock, upon approval. This grant shall have a five-year term and vest 25% on the first anniversary date of the grant, 8.33% on the 20th month of the grant, and 8.33% every 4 months thereafter. The exercise price shall be the closing price as reported on the New York Stock Exchange on the
Effective Date, the date on which Employee has begun his employment with Employer and has begun to perform the services set forth within this Agreement, or on the date that appropriate approval has been obtained, whichever is later. The terms of the
SSARS grant will be reflected in a separate agreement to be signed by Employer and Employee. 
 2.6 Management Share Ownership Policy.
Employee shall review and understand the terms of the Management Share Ownership Policy with respect to all equity-based awards. 
 2.7
Indemnification. Employer agrees to indemnify Employee against and in respect of any and all claims, actions, or demands, to the extent permitted by the Company’s By-laws and applicable law. Employer also agrees to cover Employee under
its professional liability policy, which would, among other things, provide insure coverage to the Company and Employee for any claims of malpractice arising from or related to Employee’s performance of his duties under this Agreement.

 2.8 Reimbursement. Employer also agrees to reimburse Employee in accordance with Employer’s reimbursement policies for travel
and entertainment expenses, as well as other business-related expenses, incurred in the performance of his duties hereunder. Such business-related expenses may include, but are not limited to, professional license fees, professional organization
fees, and educational materials, so long as such expenses are reasonable. Employee may travel by first class whenever he travels for business. 
 2.9 Changes to Benefit Plans. Employer reserves the right to modify, suspend, or discontinue any and all of its health and welfare benefit plans, practices, policies, and 

  

 2 

 
programs at any time without recourse by Employee so long as such action is taken generally with respect to all other similarly-situated peer executives and
does not single out Employee. 
 Section 3. Provisions Relating to Termination of Employment. 
 3.1 Employment Is At-Will. Employee’s employment with Employer is “at will” and is terminable by Employer or by Employee at any time
and for any reason or no reason, subject to the notice requirements set forth below. 
 3.2 Termination for Material Cause. Employer
may terminate Employee’s employment without advanced notice for Material Cause (as defined below). Upon termination for Material Cause, Employee shall (i) be entitled to receive the Base Salary and benefits as set forth in
Section 2.1 and Section 2.2, respectively, through the effective date of such termination and (ii) not be entitled to receive any other compensation, benefits, or payments of any kind, except as otherwise required by law
or by the terms of any benefit or retirement plan or other arrangement that would, by its terms, apply. 
 3.3 Other Termination.
Employer may terminate the employment of Employee for any reason or for no reason at any time upon at least thirty (30) days’ advance written notice. If Employer terminates the employment of Employee for reasons other than for death,
Material Cause, or Disability, or if Employee resigns for Good Reason (as defined below), and contingent upon Employee’s execution of the Employer’s standard Severance and General Release Agreement within twenty-eight days of the
termination of Employee’s employment, Employee shall be entitled to the benefits set forth in the DaVita Inc. Severance Plan (the “Severance Plan”), pursuant to the terms and conditions of that plan as they exist at the time of the
termination of Employee’s employment; provided, however, that the minimum severance Employee shall receive is salary continuation for a period of twelve months, subject to the terms and conditions of the Severance Plan. In
addition, if Employee elects to receive COBRA benefits, Employer shall share the costs of the COBRA insurance premiums by paying the same percentage of the cost of insurance coverage as it did before the termination of Employee’s employment for
the first twelve months of COBRA insurance coverage or until Employee is eligible for health insurance under his new employer’s benefit plan, whichever occurs first. For purposes of this provision, an Employee’s employment has been
terminated when Employee is no longer providing services for Employer after a specific date or the level of bona fide services that Employee would perform (as an employee or independent contractor) after a specific date would permanently decrease to
no more than 20% of the average level of bona fide services performed over the immediately preceding thirty-six month period (or the full period of service if Employee was employed for less than thirty-six months). 
 3.4. Voluntary Resignation. Employee may resign from Employer at any time upon at least thirty (30) days’ advance written notice. If
Employee resigns from Employer for any reason other than Good Reason, Employee shall (i) be entitled to receive the base salary and benefits as set forth in Section 2.1 and Section 2.2, respectively, through the
effective date of such termination and (ii) not be entitled to receive any other compensation, benefits, or payments of any kind, except as otherwise required by law or by the terms of any benefit or retirement plan 

  

 3 

 
or other arrangement that would, by its terms, apply. In the event Employee resigns from Employer at any time, Employer shall have the right to make such
resignation effective as of any date before the expiration of the required notice period. 
 3.5 Disability. Upon thirty
(30) days’ advance notice (which notice may be given before the completion of the periods described herein), Employer may terminate Employee’s employment for Disability (as defined below). 
 3.6 Definitions. For the purposes of this Agreement, the following terms shall have the meanings indicated: 
 (a) “Disability” shall mean the inability, for a period of six (6) months, to adequately perform Employee’s regular duties, with or
without reasonable accommodation, due to a physical or mental illness, condition, or disability. 
 (b) “Good Reason” shall mean
the occurrence of the following events without Employee’s express written consent: (i) Employer materially diminishes the scope of Employee’s duties and responsibilities; (ii) Employer takes away Employee’s title of Chief
Medical Officer, removes the associated Chief Medical Officer responsibilities, and does not provide Employee with an equivalent or greater title and equivalent or greater responsibilities; (iii) Employer reduces Employee’s base salary,
bonus arrangement, or other material benefits (unless the change is taken generally with respect to all similarly-situated peer executives and does not single out Employee); or (iv) the principal office to which Employee is required to report
is changed by more than twenty (20) miles (this provision is not applicable if Employer arranges for new office space for Employee that is within 20 miles of his previous office space). 
 (c) “Material Cause” shall mean any of the following: (i) conviction of a felony or plea of no contest to a felony; (ii) any act of
fraud or dishonesty in connection with the performance of his duties; (iii) repeated failure or refusal by Employee to follow policies or directives reasonably established by the Chief Executive Officer of Employer or his/her designee that goes
uncorrected for a period of ten (10) consecutive days after written notice has been provided to Employee; (iv) a material breach of this Agreement; (v) any gross or willful misconduct or gross negligence by Employee in the performance
of his duties; (vi) egregious conduct by Employee that brings Employer or any of its subsidiaries or affiliates into public disgrace or disrepute; (vii) an act of unlawful discrimination, including sexual harassment; (viii) a
violation of the duty of loyalty or of any fiduciary duty; or (ix) exclusion or notice of exclusion of Employee from participating in any federal health care program. Before the Employer may discharge Employee for an act of unlawful
discrimination, including sexual harassment, or a violation of the duty of loyalty or of any fiduciary duty, Employee shall have a right to contest his termination to one member of the Board of Directors, who shall have the discretion to take
Employee’s concerns to the entire Board of Directors. 
 3.7 Notice of Termination. Any purported termination of Employee’s
employment by Employer or by Employee shall be communicated by a written Notice of Termination to the other party hereto in accordance with Section 5 hereof. A “Notice of 

  

 4 

 
Termination” shall mean a written notice that indicates the specific termination provision in this Agreement. 
 3.8 Effect of Termination. Upon termination, this Agreement shall be of no further force and effect and neither party shall have any further right
or obligation hereunder; provided, however, that no termination shall modify or affect the rights and obligations of the parties that have accrued prior to termination; and provided further, that the rights and obligations of the
parties under Section 3, Section 4, and Section 5 shall survive termination of this Agreement. 
 3.9
Notwithstanding any provision herein to the contrary, in the event that any payment to be made to Employee hereunder (whether pursuant to this Section 3 or any other Section) as a result of Employee’s termination of employment is
determined to constitute “deferred compensation” subject to Section 409A of the Internal Revenue Code, and Employee is a “Key Employee” under the DaVita Inc. Key Employee Policy for 409A Arrangements at the time of
Employee’s termination of employment, all such deferred compensation payments payable during the first six (6) months following Employee’s termination of employment shall be delayed and paid in a lump sum during the seventh calendar
month following the calendar month during which Employee’s termination of employment occurs. 
 Section 4: Non-Solicitation,
Non-Competition and Confidentiality. Employee, contemporaneously herewith, shall enter into a Non-Solicitation, Non-Competition and Confidentiality Agreement, the terms of which are incorporated herein and made a part hereof as though set forth
in this Agreement. 
 Section 5. Compliance with Laws 
 5.1 Compliance with Fraud and Abuse Laws. It is understood that neither Employer nor Employee intends to violate the federal Medicare and Medicaid Anti-Kickback Statute and/or the federal Physician
Self-Referral Statute, or any other law, rule, or regulation applicable to this Agreement, as such laws, rules, or regulations are amended from time to time. Accordingly, nothing in this Agreement shall be interpreted to require any referral of
patients by Employee, or any entity related to Employee to Employer, or any entity related to Employer. Furthermore Employer has no intent to influence the judgment of Employee regarding where Employee, or any entity related to Employee refers
patients for any services. In the event any law is adopted or amended, any rule or regulation is promulgated or amended, any administrative ruling, interpretation, or pronouncement is made, or any judicial interpretation is issued which either party
reasonably believes creates an unreasonable risk that this Agreement violates any applicable state or federal law, regulation, ruling, or order such party may request amendments or modifications to this Agreement which such party reasonably believes
are necessary to avoid such violation, and, if this Agreement is not modified or amended in a mutually agreeable manner within thirty (30) days after such amendments or modifications are first proposed, either party may immediately terminate
this Agreement. 
  

 5 

 5.2 Health Insurance Portability and Accountability Act. Employee shall comply with the applicable
provisions of the Administrative Simplification section of the Health Insurance Portability and Accountability Act of 1996, as codified at 42 U.S.C. § 1320 through d-8 (“HIPAA”), the requirements of any regulations promulgated
thereunder, including, without limitation, the federal privacy regulations and the federal security standards as contained in 45 C.F.R. Part 164 (collectively, the “Regulations”), and Employer’s policies and procedures in connection
with HIPAA. Employee shall not use or further disclose any protected health information as defined by the Regulations other than as permitted by this Agreement and the requirements of HIPAA or the Regulations. Employee shall promptly report to
Employer any use or disclosure, of which Employee becomes aware, of protected health information in violation of HIPAA, the Regulations, or Employer’s policies and procedures. The provisions set forth herein shall survive expiration or other
termination of this Agreement, regardless of the cause of such termination. 
 Section 6. Miscellaneous. 
 6.1 Entire Agreement; Amendment. This Agreement represents the entire understanding of the parties hereto with respect to the employment of
Employee and supersedes all prior agreements with respect thereto. This Agreement may not be altered or amended except in writing executed by both parties hereto. 
 6.2 Assignment; Benefit. This Agreement is personal and may not be assigned by Employee. This Agreement may be assigned by Employer and shall inure to the benefit of and be binding upon the successors and
assigns of Employer. 
 6.3. Notice. Notices and all other communications provided for in this Agreement shall be in writing and shall
be deemed to have been duly given when delivered or mailed by United States registered mail, return receipt requested, postage prepaid, addressed to Employer at its principal office and to Employee at Employee’s principal residence as shown in
Employer’s personnel records, provided that all notices to Employer shall be directed to the attention of the Chief Executive Officer, or to such other address as either party may have furnished to the other in writing in accordance herewith,
except that notice of change of address shall be effective only upon receipt. 
 6.4 Construction. Each party has cooperated in the
drafting and preparation of this Agreement. Hence, in any construction to be made of this Agreement, the same shall not be construed against any party on the basis that the party was the drafter. The captions of this Agreement are not part of the
provisions hereof and shall have no force or effect. 
 6.5 Execution. This Agreement may be executed in one or more counterparts,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Photographic or facsimile copies of such signed counterparts may be used in lieu of the originals for any purpose. 
  

 6 

 6.6 Legal Counsel. Employee and Employer recognize that this is a legally binding contract and
acknowledge and agree that they have had the opportunity to consult with legal counsel of their choice. 
 6.7 Waiver. The waiver by
any party of a breach of any provision of this Agreement by the other shall not operate or be construed as a waiver of any other or subsequent breach of such or any provision. 
 6.8 Invalidity of Provision. In the event that any provision of this Agreement is determined to be illegal, invalid, or void for any reason, the
remaining provisions hereof shall continue in full force and effect. 
 6.9 Approval by DaVita Inc. as to Form. The parties
acknowledge and agree that this Agreement shall take effect and be legally binding upon the parties only upon full execution hereof by the parties and upon approval by DaVita Inc. as to the form of hereof. 
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement effective as of the date and year first written above. 
  

									
	DAVITA INC.	 		 	ALLEN NISSENSON
					
	By	 	 /s/    DENNIS KOGOD
	 		 	By	 	 /s/    ALLEN NISSENSON

		 	Dennis Kogod	 		 		 	
		 	President - West	 		 		 	

 Approved by DaVita Inc. as to Form: 
  

	
	 /s/    STEVEN M. COOPER

	Steven M. Cooper
	Assistant General Counsel - Labor

  

 7Form of Stock Appreciation Rights Agreement

 Exhibit 10.3 
 Stock Appreciation Rights Agreement under 
 the DaVita Inc. 2002 Equity Compensation Plan

 - Board of Directors 
  

			
	 Primary Terms
	  	 
		
	Grantee:	  	Sample Example
		
	SSN:	  	123-45-6789
		
	Address:	  	1234 Any Street
		  	Apt. #A
		  	Any Town, US 12345
		
	Grant Date:	  	January 1, 2008
		
	Base Shares Granted:	  	12,000
		
	Base Price per Share:	  	$55.0000
		
	Expiration Date:	  	January 1, 2013
		
	Plan Name:	  	2002 Equity Compensation Plan
		
	Plan ID#:	  	2002
		
	Vesting Schedule:	  	100% after 1 year
		
		  	12,000 on 01/01/2009

 The terms set forth above, together with the terms and conditions attached, constitute one agreement.

 Note: Please mark and initial any correction to the Name, SSN and/or Address shown on this page before returning a signed copy of this agreement to
the Stock Plan Administrator. 

 This Stock Appreciation Rights Agreement is dated as of January 1, 2008 (“Grant
Date”) by and between DaVita Inc., a Delaware corporation (“Company”) and Sample Example (“Grantee”) pursuant to the Company’s 2002 Equity Compensation Plan (“Plan”). Capitalized terms that are
used but not defined in this document shall have the meanings set forth in the Plan. 
 1. Grant of SAR. 
 The Company hereby grants to the Grantee the right (“SAR”) to receive with respect to all or any portion of 12,000 shares (“ Base
Shares”) of the common stock of the Company (“Common Stock”) a number of shares (“Gain Shares”) of Common Stock with a Fair Market Value equal to the amount by which the Fair Market Value applicable to one share of Common
Stock on the date on which the SAR is exercised exceeds a base price of $50.0000 per share (“Base Price”). 
 2. Term
of SAR. 
 (a) This SAR shall be effective for the period (“Term”) from the Grant Date shown above through
January 1, 2013 (“Expiration Date”). 
 (b) This SAR shall expire and cease to be exercisable on the earlier to occur
of: 
 (i) the Expiration Date, 
 (ii) the date which is three (3) months after the date on which the Grantee’s membership on the Board of Directors of the Company terminates unless such termination is the result of Grantee’s death (or Grantee dies during the
three (3) month period following the termination of his or her membership on the Board of Directors of the Company) or Grantee was disabled (within the meaning of Section 22(e)(3) of the Code) at the time of such termination of membership
on the Board of Directors of the Company, or 
 (iii) the date which is one (1) year from the date of termination of Grantee’s
membership on the Board of Directors if such termination is the result of Grantee’s death (or Grantee dies during the three (3) month period following the termination of his or her membership on the Board of Directors of the Company) or
Grantee was disabled (within the meaning of Section 22(e)(3) of the Code) at the time of such termination of membership on the Board of Directors. 
 3. Exerciseability. 
 (a) The Base Shares subject to this SAR shall become exerciseable
(“vest”) on the dates indicated under the Vesting Schedule above such that this SAR shall be fully exerciseable on the last date listed on such table; provided, however, that such vesting shall cease at the time Grantee ceases to be a
member of the Company’s Board of Directors. 
 (b) These installments shall be cumulative, so that this SAR may be exercised as to any
or all of the Base Shares covered by an installment at any time or times after the installment becomes vested and until this SAR terminates. 
 (c) The foregoing notwithstanding, in the event that either (i) in connection with a “Change of Control” (defined below), the “Acquiror” (defined below) fails to assume, convert or replace this Award, or
(ii) your Board service is terminated within the twenty-four (24) month period following a Change of Control by the Company (or the Acquiror) other than for “Cause” (defined below), then, in any such case, the SAR shall
automatically vest and become immediately exercisable in its entirety, such vesting to be effective as of immediately prior to the effective date of the Change of Control in the case of (i), and as of the date of termination of the Grantee’s
service in the case of (ii). 
 A “Change of Control” is defined herein as (i) any transaction or series of transactions in which any person
or group (within the meaning of Rule 13d-5 under the Exchange Act and Sections 13(d) and 14(d) under the Exchange Act) becomes the direct or indirect “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), by way of a stock
issuance, tender offer, merger, consolidation, other business combination or otherwise, of greater than 50% of the total voting power (on a 

 
fully diluted basis as if all convertible securities had been converted and all warrants and options had been exercised) entitled to vote in the election of
directors of the Company (including any transaction in which the Company becomes a wholly-owned or majority-owned subsidiary of another corporation), or 
 (ii) any transaction in which assets representing more than 50% of the total gross fair market value of the Company’s assets are sold, provided, however, that no transaction contemplated by clauses (i) through (ii) above
shall constitute a Change of Control if both (x) the person acting as the Chief Executive Officer of the Company for the 6 months prior to such transaction becomes the Chief Executive Officer or Executive Chairman of the Board of Directors of
the entity that has acquired control of the Company as a result of such transaction (the “Acquiror”) immediately after such transaction and remains the Chief Executive Officer or Executive Chairman of the Board of Directors for not less
than one year following the transaction and (y) a majority of the Acquiror’s board of directors immediately after such transaction consist of persons who were directors of the Company immediately prior to such transaction. 
 Cause will mean: (1) a material breach by you of your duties and responsibilities to the extent that do not differ in any material respect from your duties and
responsibilities during the ninety (90)-day period immediately prior to a Change in Control (other than as a result of incapacity due to physical or mental illness) which is demonstrably willful and deliberate on your part, which is committed in bad
faith or without reasonable belief that such breach is in the best interests of the Company and which is not remedied in a reasonable period of time after receipt of written notice from the Company specifying such breach; (2) willful misconduct
or gross negligence which results in material harm to the Company; or (3) your conviction of, or a plea of nolo contendere by the you, to a felony or other crime involving fraud or dishonesty; or (4) willful violation of Company
policies which results in material harm to the Company. 
 (d) In the event that the Grantee ceases to be a member of the Company’s
Board of Directors (whether by reason of death or otherwise), the number of Base Shares with respect to which this SAR may be exercised shall not be accelerated. 
 4. Method of Exercising. 
 This SAR may be exercised by the Grantee upon delivery of the
following documents to the Company at its principal executive offices: 
 (a) Written notice, in the form of a completed exercise election
form, specifying the number of full Shares with respect to which the SAR is being exercised; and 
 (b) Such agreements or undertakings that
are required by the Committee pursuant to the Plan. 
 5. Settlement of SAR. 
 Upon exercise of the SAR, in whole or in part, the Company shall: 
 (1) provide for the registration in book-entry form for the Grantee’s benefit of the Gain Shares (rounded down to the nearest whole number), or 
 (2) deliver to the Grantee a stock certificate representing the Gain Shares (rounded down to the nearest whole number). 
 6. Assignments. 
 (a) This SAR
shall be exerciseable only by the Grantee during the Grantee’s lifetime. 
 (b) The rights of the Grantee under this SAR may not be
assigned or transferred except by will or by the laws of descent and distribution. 
 7. No Rights as a Stockholder.

 The Grantee shall have no rights as a stockholder of any Base Shares or Gain Shares unless and until Gain Shares are issued to him or
her following the exercise of this SAR. 

 8. Interpretation of SAR.  
 (a) This SAR is made under the provisions of the Plan and shall be interpreted in a manner consistent with it. 
 (b) Any provision in this SAR inconsistent with the Plan shall be superseded and governed by the Plan. 
 9. Restrictions on Transfer of Gain Shares. 
 The Grantee acknowledges that any Gain Shares issued upon exercise of this SAR may be subject to such restrictions on transfer as the Company may deem necessary to comply with all applicable state and federal
securities laws and regulations. 
 10. Amendments. 
 This SAR may be amended at any time with the consent of the Company and the Grantee. 
 11. Confidentiality. 
 Grantee
shall not at any time disclose or use for Grantee’s direct or indirect personal benefit or purposes or for the benefit or purposes of any person, firm, partnership, joint venture, association, corporation, or other business organization, entity
or enterprise other than the Company or any of its subsidiaries or affiliates (whether during or after the termination of Grantee’s membership on the Board of Directors of the Company), any trade secret, information, data or other confidential
information relating to customers, development programs, costs, marketing plans, acquisitions and investments, sales activities, promotions, credit and financial data, financing methods, plans of the business and affairs of the Company generally, or
any of its subsidiaries or affiliates; provided, however, that the foregoing shall not apply to (i) information which is not unique to the Company or which is generally known to the industry or the public other than as a result of
Grantee’s breach of this Section 11 or (ii) disclosure that is required by any applicable law, rule or regulation (including compliance with any oral or written interrogatories or requests for information or documents pursuant to any
subpoena or in connection with discovery proceedings in any litigation or similar process to which Grantee may be subject); provided, however, that Grantee shall provide the Company with at least ten (10) days’ advance
written notice of the legal requirement to disclose prior to disclosure and assist DaVita as requested in obtaining a protective order or other similar relief. 
 12. Non-Solicitation. 
 Grantee agrees that while Grantee is a member of the Company’s
Board of Director’s and for the one-year period following termination of such relationship, Grantee will not (a) directly or indirectly induce any employee of the Company, its affiliates or its subsidiaries to terminate his or her
relationship with the Company or any of its affiliates or subsidiaries or (b) take any action that results, or might reasonably result in any of the foregoing. If Grantee breaches this provision, then (1) this SAR shall terminate effective
on the date on which Grantee enters into such activity and (2) the Company may seek temporary, preliminary, and permanent injunctive relief to prevent any actual or threatened breach or continuation of any breach of this Agreement without the
necessity of proving actual damages or posting a bond or other security (which Grantee hereby agrees to) and/or an order requiring Grantee to repay the Company any gain realized by Grantee from exercising all or a portion of this Grant. 

This agreement may be considered null and void at the discretion of the Company if a signed copy is not returned to the Stock Plan Administrator for
the Company NO LATER THAN February 28, 2008. 
 In Witness Whereof, the Company and the Grantee have executed this SAR as of the date
first written above. 
  

					
	 Grantee
	  	 	  	 Company

			
	  
	  		  	  

	Printed Name	  		  	Printed Name
			
	  
	  		  	  

	Signature	  		  	Signature
			
		  		  	  

		  		  	Title

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]